Navigation Links
Medicago to present at the U.S. Department of Health and Human Services' Global Health Security Initiative Workshop
Date:11/4/2009

QUEBEC CITY, Nov. 4 /PRNewswire-FirstCall/ - Medicago Inc. (TSX-V: MDG), a biotechnology company focused on developing highly effective and affordable vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), today announced that it received an invitation from the U.S. Department of Health and Human Services (HHS) to present at the Global Health Security Initiative Workshop (GHSI) on November 5, 2009 at 2:40 pm (EST) at the Fairfax at Embassy Row Hotel, Washington, D.C. During a session entitled Diagnostics and Vaccine Development Platforms, Medicago will discuss its ability to potentially improve the speed, capacity and cost of influenza vaccine production with its proprietary plant-based manufacturing platform and VLP technology.

The GHSI is an international, high-level forum for like-minded countries to discuss public health preparedness for chemical, biological, and radiological/nuclear (CBRN) threats as well as pandemic influenza. Amongst the GHSI policy priorities, the GHSI partners agreed on the need to build a global infrastructure for medical countermeasures (MCM). This year's workshop will provide an international opportunity for academia and industry partners to discuss research and development programs, products and new technologies as a first step towards coordinating preparedness efforts.

About Medicago

Medicago is committed to provide highly effective and affordable vaccines based on proprietary Virus-Like Particle (VLP) and manufacturing technologies. Medicago is developing VLP vaccines to protect against H5N1 pandemic influenza, using a transient expression system which produces recombinant vaccine antigens in non-transgenic plants. This technology has potential to offer advantages of speed and cost over competitive technologies. It could deliver a vaccine for testing in about a month after the identification and reception of genetic sequences from a pandemic strain. This production time frame has the potential to allow vaccination of the population before the first wave of a pandemic strikes and to supply large volumes of vaccine antigens to the world market. Additional information about Medicago is available at www.medicago.com.

Forward Looking Statements

This press release contains forward-looking statements which reflect Medicago's current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual results could differ materially from those projected herein. Medicago disclaims any obligation to update these forward-looking statements.

    Neither TSX Venture Exchange nor its Regulation Services Provider (as
    that term is defined in the policies of the TSX Venture Exchange) accepts
    responsibility for the adequacy or accuracy of this release

SOURCE Medicago Inc.


'/>"/>
SOURCE Medicago Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Medicago awarded contract by the U.S. Army to explore applications of its plant-based technology in renewable energy
2. Medicago begins human clinical testing with its avian flu pandemic vaccine
3. Medicago receives regulatory approval to begin human clinical testing with its avian flu pandemic vaccine
4. Medicagos H1N1 pandemic vaccine candidate shows positive response in 100% of vaccinated animals after a single dose
5. Medicago succesfully expresses VLP antigen for A H1N1 strain
6. Medicago initiates work on Swine Flu strain
7. Sangamo BioSciences Announces Presentation at Merriman Curhan Fords Investor Summit 2009
8. YM BIOSCIENCES REPORTS POSITIVE NIMOTUZUMAB FOUR-YEAR SURVIVAL DATA PRESENTED AT ASTRO 2009
9. Sanofi Pasteur Presents Safety Data on Menactra(R) Vaccine Given to Infants at Infectious Disease Society Meeting
10. Additional Data From Fidaxomicins Phase 3 Study for Clostridium Difficile Infection (CDI) Presented at IDSA Annual Meeting
11. ViroPharma to Present at Three November Healthcare Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... October 12, 2017 , ... ... prospective clinical study that demonstrates the accuracy of the FebriDx® test, a ... significant acute bacterial and viral respiratory tract infections by testing the body’s ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... analysis platform specifically designed for life science researchers to analyze and interpret ... Rosalind Franklin, who made a major contribution to the discovery of the ...
(Date:10/11/2017)... ... ... is a basic first aid supply for any work environment, but most personal eye wash ... if a dangerous substance enters both eyes? It’s one less decision, and likely quicker response ... piece. , “Whether its dirt and debris, or an acid or alkali, getting anything in ...
(Date:10/11/2017)... Oct. 11, 2017  VMS BioMarketing, a leading provider of ... oncology Clinical Nurse Educator (CNE) network, which will launch this ... communication among health care professionals to enhance the patient care ... staff, and other health care professionals to help women who ... ...
Breaking Biology Technology:
(Date:4/5/2017)... April 5, 2017 Today HYPR Corp. ... the server component of the HYPR platform is officially ... the end-to-end security architecture that empowers biometric authentication across ... has already secured over 15 million users across the ... of connected home product suites and physical access represent ...
(Date:3/30/2017)... , March 30, 2017  On April 6-7, 2017, ... the Genome hackathon at Microsoft,s headquarters in ... competition will focus on developing health and wellness apps ... Hack the Genome is the first hackathon ... The world,s largest companies in the genomics, tech and ...
(Date:3/28/2017)... , March 28, 2017 The ... Hardware (Camera, Monitors, Servers, Storage Devices), Software (Video Analytics, ... Region - Global Forecast to 2022", published by MarketsandMarkets, ... 2016 and is projected to reach USD 75.64 Billion ... and 2022. The base year considered for the study ...
Breaking Biology News(10 mins):